<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table id="schedule" border="0" cellspacing="0" summary="This table shows the date, time, and location of the meeting" cellpadding="2" style="width: 643px"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th id="a1" bgcolor="#cccccc" valign="top" align="left" style="width: 59px"&gt;Center&lt;/th&gt;&lt;th id="a2" bgcolor="#cccccc" valign="top" align="left" style="width: 108px"&gt;Date&lt;/th&gt;&lt;th id="a3" bgcolor="#cccccc" valign="top" align="left" style="width: 163px"&gt;Time&lt;/th&gt;&lt;th id="a4" bgcolor="#cccccc" valign="top" align="left" style="width: 193px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td height="61" valign="top" headers="a1" style="width: 59px"&gt;CDER&lt;/td&gt;&lt;td valign="top" headers="a2" style="width: 108px"&gt;October 20, 2014&lt;/td&gt;&lt;td valign="top" headers="a3" style="width: 163px"&gt;8:00 a.m. to 5:00 p.m.&lt;/td&gt;&lt;td valign="top" headers="a4" style="width: 193px"&gt;FDA White Oak Campus&lt;br /&gt;Building 31&lt;br /&gt;The Great Room (Rm. 1503)&lt;br /&gt;White Oak Conference Center&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;Silver Spring, Maryland&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;&lt;strong&gt;&lt;font face="Verdana"&gt;Agenda&lt;/font&gt;&lt;/strong&gt;&lt;/p&gt;&lt;div&gt;&lt;font face="Verdana"&gt;The committee will discuss biologics license application (BLA) 125504, secukinumab, a human monoclonal antibody, submitted by Novartis, proposed for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. &lt;/font&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;&lt;font face="Verdana"&gt;Meeting Materials&lt;br /&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;font face="Verdana"&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting.&amp;nbsp; If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&amp;nbsp; &lt;/font&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;Background Materials&lt;br /&gt;&lt;br /&gt;&lt;/strong&gt;&lt;/div&gt;&lt;ul&gt;&lt;li&gt;&lt;a target="" href="[!--$wcmUrl('link','UCM404866')--]"&gt;2014 Meeting Materials, Dermatologic and Ophthalmic Drugs Advisory Committee&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;&lt;font face="Verdana"&gt;Public Participation Information&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;font face="Verdana"&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/font&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;ul&gt;&lt;li&gt;&lt;font face="Verdana"&gt;Written submissions may be made to the contact person on or before&lt;br /&gt;&lt;/font&gt;&lt;font face="Verdana"&gt;October 3, 2014.&lt;/font&gt;&lt;/li&gt;&lt;li&gt;&lt;font face="Verdana"&gt;Oral presentations from the public will be scheduled between approximately 1:00 p.m. to &lt;/font&gt;&lt;font face="Verdana"&gt;2:00 p.m. on October 20, 2014.&amp;nbsp; Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before September 25, 2014.&lt;/font&gt;&lt;/li&gt;&lt;/ul&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;font face="Verdana"&gt;Time allotted for each presentation may be limited.&amp;nbsp; If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.&amp;nbsp; The contact person will notify interested persons regarding their request to speak by September 26, 2014.&lt;/font&gt;&lt;/div&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Webcast Information&lt;/strong&gt;&lt;/p&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;CDER plans to provide a free of charge, live webcast of the October 20, 2014, meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee.&amp;nbsp; While CDER is working to make webcasts available to the public for all advisory committee meetings held at the White Oak campus, there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible.&amp;nbsp; Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: &lt;a href="http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm"&gt;http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm&lt;/a&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/div&gt;&lt;p style="margin-left: 40px"&gt;Moon Hee V. Choi, Pharm.D.&lt;br /&gt;Center for Drug Evaluation and Research&lt;br /&gt;Food and Drug Administration&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;WO31-2417&lt;br /&gt;Silver Spring, MD&amp;nbsp; 20993-0002&lt;/p&gt;&lt;div style="margin-left: 40px"&gt;Phone: 301-796-9001&lt;br /&gt;Fax: 301-847-8533&lt;br /&gt;Email: &lt;a href="mailto:DODAC@fda.hhs.gov"&gt;DODAC@fda.hhs.gov&lt;/a&gt;&lt;/div&gt;&lt;div style="margin-left: 40px"&gt;&lt;br /&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington DC area) &lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/div&gt;&lt;div style="margin-left: 40px"&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.&amp;nbsp; Therefore, you should always check the agency&amp;rsquo;s Web site and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.&amp;nbsp; FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Moon Hee V. Choi at (301) 796-9001 at least 7 days in advance of the meeting.&amp;nbsp;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;Information regarding ground transportation, airport information, lodging, driving directions and visitor parking, and security can be accessed at: &lt;a target="" href="[!--$wcmUrl('link','UCM241740')--]"&gt;Public Meetings at the FDA White Oak Campus&lt;/a&gt;.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;FDA is committed to the orderly conduct of its advisory committee meetings.&amp;nbsp; Please visit our Web site at &lt;a target="" href="[!--$wcmUrl('link','UCM111462')--]"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;br /&gt;&amp;nbsp;&lt;/div&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
